← Search & browse all drugs
RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › Xanthines and adrenergics
proxyphylline and adrenergics
R03DB03
Forms & Strengths
- Combination oral tablets containing proxyphylline and adrenergic bronchodilators
- Syrup formulations varying by specific regional manufacturer
Adult Dosing
- Proxyphylline component typically 100 mg to 250 mg orally 3 to 4 times daily
- Dose titrated based on clinical response and tolerance of the adrenergic component
Pediatric Dosing
- Safety and efficacy not well established in pediatric patients under 12 years
- Use in children generally discouraged due to unpredictable pharmacokinetics of xanthine-adrenergic combinations
Indications
- Symptomatic relief of bronchial asthma
- Reversible bronchospasm associated with chronic bronchitis and emphysema
Mechanism of Action
- Proxyphylline acts as a phosphodiesterase inhibitor, causing mild bronchodilation and anti-inflammatory effects
- Adrenergic component stimulates beta-2 receptors in bronchial smooth muscle, increasing cAMP and producing bronchodilation
Contraindications
- Hypersensitivity to xanthines, proxyphylline, or sympathomimetic amines
- Pre-existing severe cardiovascular disease, arrhythmias, or tachycardias
- Recent myocardial infarction
- Concomitant use with other sympathomimetic agents
Adverse Reactions
- Palpitations, tachycardia, and cardiac arrhythmias
- Tremors, nervousness, and anxiety
- Insomnia and headache
- Nausea, vomiting, and gastrointestinal irritation
Drug Interactions
- Additive sympathomimetic toxicity when combined with other adrenergic agents
- Increased risk of hypokalemia with loop diuretics or corticosteroids
- Beta-blockers antagonize the bronchodilatory effects of the adrenergic component and may provoke bronchospasm
- Potential for enhanced CNS stimulation when combined with other stimulants
Curated Content: Needs Vetting Before Put to Clinical Use